Key Takeaways
- Shares of NVS dropped approximately 2% during pre-market trading following disappointing Q1 results
- Revenue reached $13.11B, missing analyst projections of $13.40B, representing a 1% year-over-year decline
- Entresto revenue plummeted 42% to $1.31B following U.S. patent expiration and generic market entry
- Core earnings per share declined to $1.99 compared to $2.28 previously; core operating profit decreased 12% to $4.9B
- CEO Vas Narasimhan highlighted concerns that U.S. “most favored nation” drug pricing measures could restrict patient access to innovative treatments in Europe and Japan within an 18-month timeframe
Novartis delivered disappointing first-quarter 2026 performance, falling short of Wall Street expectations across both revenue and profitability metrics as generic competition proved more severe than anticipated.
Revenue totaled $13.11 billion, missing the $13.40 billion analyst consensus. Core operating profit decreased 12% to $4.9 billion, falling below the approximately $5.1 billion estimate from Visible Alpha.
The primary driver behind the underperformance was Entresto, the company’s leading cardiovascular medication. Revenue from this treatment plunged 42% to $1.31 billion following U.S. patent expiration and subsequent generic market entry. Wall Street had anticipated $1.37 billion.
Entresto represented 14% of total revenue during the previous year, marking this as one of the most significant patent cliff events in the company’s recent timeline. CEO Vas Narasimhan has characterized this as the most substantial patent expiration Novartis has encountered over the past two decades.
Entresto stands alongside other challenged products. Promacta, used for blood disorders, and Tasigna, a leukemia medication, are experiencing similar generic market pressures, compounding the challenges to revenue expansion.
Core earnings per share decreased to $1.99 from $2.28 during the comparable prior-year period. Operating income contracted 9% while net income fell 13%, driven by the revenue shortfall combined with elevated research expenditures.
CFO Mukul Mehta informed reporters that the performance aligned with internal projections. He indicated the company anticipates “growth to return back to our P&L in the second half of this year.”
Novartis maintained its full-year outlook, citing a robust pipeline and continued drug commercialization efforts. The pharmaceutical giant projects approximately $4 billion in annual sales erosion attributed to generic competition affecting Entresto, Promacta, and Tasigna.
CEO Raises Concerns About MFN Policy Impact
Beyond the quarterly financial results, CEO Narasimhan utilized the earnings release to voice apprehensions regarding U.S. pharmaceutical pricing regulations, particularly the “most favored nation” framework.
The MFN approach links U.S. medication prices to those established in other developed nations. Narasimhan cautioned that the ramifications would extend internationally, stating “the reality of MFN is going to set in in the next 18 months.”
He indicated that Novartis is urging Europe and Japan to reconsider their pricing frameworks and innovation incentives. Absent such modifications, he cautioned that “novel medicines might see delayed entry” and patient accessibility could deteriorate.
Currently, the immediate financial impact on Novartis remains modest. MFN presently affects approximately 5% to 10% of Medicaid-related revenue. However, Narasimhan views the policy as permanent. “I don’t see it disappearing in the U.S.,” he stated.
His remarks align with statements from industry counterparts. Roche and AstraZeneca have similarly identified Europe’s pricing mechanisms as an escalating threat to future medication accessibility.
Analyst Sentiment Remains Constructive
The quarterly shortfall has yet to shift fundamental analyst positioning on the stock. Novartis maintains a Moderate Buy consensus rating supported by six analyst recommendations.
The mean price target stands at $169.86, suggesting approximately 17% potential appreciation from present trading levels.
Entresto will encounter European patent expirations beginning in November, which will introduce additional revenue headwinds during the year’s latter half.
